Anzeige
Mehr »
Login
Mittwoch, 08.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Diese Aktie hebt ab: +130,67% Kursgewinn in 1 Monat – das sind die Gründe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
18 Leser
Artikel bewerten:
(0)

Maxygen, Inc. Announces Final Results of Dutch Auction Tender Offer

REDWOOD CITY, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Maxygen, Inc. , a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced the final results of its modified "Dutch Auction" tender offer, which expired at 5:00 p.m., New York City time, on December 23, 2009.

Maxygen has accepted for purchase 7,345,103 shares in the tender offer, at a price of $5.30 per share, for a total cost of approximately $38.9 million, excluding fees and expenses related to the tender offer. Based on the depositary's final count, a total of 9,400,133 shares were validly tendered in the tender offer at a price of $5.30 per share. Accordingly, after taking into account the odd lot priority, the final proration factor for the offer was approximately 78.1%. The 7,345,103 shares to be purchased in the tender offer represent approximately 18.5% of the shares outstanding on December 28, 2009.

The total number of shares to be purchased in the tender offer include the 6,557,377 shares Maxygen initially offered to purchase, as well the 787,726 additional shares Maxygen has elected to acquire pursuant to the terms of the tender offer.

The depositary will promptly make payment for the shares accepted for purchase and will promptly return all other shares tendered and not purchased.

Stockholders and investors who have questions or need information about the tender offer may contact the Information Agent for the offering, Okapi Partners LLC at (212) 297-0720 or toll-free (877) 285-5990.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. For more information, please visit http://www.maxygen.com/.

Maxygen, Inc.

CONTACT: Patrick McHugh, or Bruce H. Goldfarb, both of Okapi Partners
LLC, +1-212-297-0720, info@okapipartners.com

Web Site: http://www.maxygen.com/

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2009 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.